Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Vaccines & Diagnostics Inc.

Division of Novartis AG

Latest From Novartis Vaccines & Diagnostics Inc.

Appointments: EFPIA, Celgene, AcelRx, PureTech Health, Symbiomix, CRISPR Therapeutics and Achaogen

This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.


US FDA Touts Value Of Phase III Trials Amid Presidential Transition

As future of agency remains uncertain, report makes the case for strict approval standards.

Drug Approval Standards Research & Development

CSL's Fluad Seems Headed For Post-Marketing Safety Study

Adjuvanted seasonal influenza vaccine should get accelerated approval but needs confirmatory trial to address imbalance in deaths following revaccination, FDA advisory committee says.

BioPharmaceutical United States

Fluad Adjuvant Could Come Under Fire At Advisory Committee

CSL’s (formerly Novartis’) flu vaccine was shown to be non-inferior, but not superior, on immunogenicity endpoints compared to an unadjuvanted vaccine in individuals ages 65 years and older.

BioPharmaceutical United States
See All

Company Information